Prospects for the Use of Artificial Intelligence in Personalized Medicine, Pharmaceutical Design and Education

Viktoria Dovzhuk (Doctor of Pedagogical Sciences, Candidate of Pharmaceutical Sciences, Associate Professor, Bogomolets National Medical University, Ukraine)
Liudmyla Konovalova (Candidate of Pedagogical Sciences, Associate Professor, Bogomolets National Medical University, Ukraine)
Natela Dovzhuk (Candidate of Pedagogical Sciences, Associate Professor, Bogomolets National Medical University, Ukraine)
Serhii Konovalov (Candidate of Medical Sciences, Associate Professor, Bogomolets National Medical University, Ukraine)
Liudmyla Konoshevych (Candidate of Pharmaceutical Sciences, Associate Professor, Bogomolets National Medical University, Ukraine)
Nataliia Motorna (Candidate of Biological Sciences, Bogomolets National Medical University, Ukraine)
Corresponding author: Viktoria Dovzhuk

Received: April 02, 2025
Published: April 17, 2025

Abstract. The article reviews modern approaches to the use of artificial intelligence in personalized medicine, pharmaceutical design and education, in particular in the pharmaceutical industry, in the processes of search, development, new drugs, personalization of pharmacotherapy and in the education of specialists in these processes. An analysis of the main areas of application of artificial intelligence, its advantages and challenges, as well as the impact on pharmaceutical design in the creation of new drugs is carried out. Special attention is paid to the role of artificial intelligence in personalized medicine, prediction of clinical and pharmacological properties, optimization of clinical trials. Ethical and regulatory aspects of integrating artificial intelligence into medical and pharmaceutical education are considered. Prospects for further development and improvement of the implementation of artificial intelligence in medicine, pharmaceutical design and education are identified. The potential for artificial intelligence to accelerate drug discovery, reduce costs, and enhance treatment precision through real-time analysis of vast datasets is particularly highlighted. Additionally, educational curricula incorporating artificial intelligence-based simulations and virtual reality tools for training future pharmaceutical professionals are explored.

Keywords: artificial intelligence, pharmaceutical design, development of new drugs, personalized medicine, clinical trials, pharmacotherapy, ethical aspects, regulatory requirements.

Introduction. Today, against the backdrop of Covid, post-Covid, and long-Covid health disorders, the issues of searching for, developing new drugs, quality control, diagnostic methods, treatment, pharmacotherapy regimens, and training specialists to perform these procedures remain relevant [1-10].

Among the latest digital technologies, artificial intelligence technologies are rapidly developing. Artificial intelligence (AI) is one of the most promising technologies of our time, which has a significant impact on various fields of science and industry, including medicine, pharmacy, and education. The use of AI in the pharmaceutical industry opens new opportunities for improving the processes of research, development, testing, and production of drugs. Thanks to machine learning (ML) and deep learning (DL) algorithms, it has become possible to significantly reduce the time and costs of developing new drugs, optimize the processes of molecule synthesis, predict the clinical and pharmacological properties, efficacy, and safety of drugs, and personalize patient treatment [11].

The development of AI in the medical and pharmaceutical sector is marked by an increase in the efficiency of production processes, increased accuracy of diagnostics, prediction of side effects and creation of innovative pharmacotherapeutic solutions. For example, through the analysis of large

volumes of biological and clinical data, AI helps to identify new targets in the pharmaceutical design of drugs, predict their interaction with potential molecules [12].

This article reviews the main areas of application of AI in personalized medicine, pharmaceutical design and education, its advantages, challenges, and development prospects.

The purpose of the study was to analyze the modern use of AI in personalized medicine, pharmaceutical design, and education. In the processes of searching, developing, testing, and personalizing new drugs. The study is aimed at identifying key areas of application of AI, assessing its advantages and challenges, as well as predicting future development trends in this area.

Materials and methods. The study is based on an analysis of scientific publications covering the use of AI in medicine, pharmaceutical design, and education. A review of literature sources was conducted, including peer-reviewed articles containing research results using machine learning (ML), deep learning (DL) and natural language processing (NLP) algorithms in the creation and optimization of medicines. Methods of comparative analysis, synthesis and generalization of the information obtained were used to assess the effectiveness of the use of AI in pharmaceutical research.

The study of the article is a fragment of research works of Private Scientific Institution "Scientific and Research University of Medical and Pharmaceutical Law" and Danylo Halytsky Lviv National Medical University on the topic "Diagnosis, treatment, pharmacotherapy of inflammatory, traumatic and onco-thoracic pathology using instrumental methods" (state registration number 0125U000071, implementation period 2025-2031) and "Multidisciplinary research of post-traumatic stress disorders during war among patients (primarily combatants)" (state registration number 0124U002540, implementation period 2024-2029); and "Interdisciplinary scientific and methodological research in the field of pharmaceuticals and veterinary medicine: innovations, modernization, technologies, regulation" (state registration number 0125U000598, implementation period 2025-2031).

Results and discussion.

Fundamentals of AI and its technologies

AI is an interdisciplinary field of computer science that aims to create systems that can imitate human intelligence. The main components of AI are machine learning (ML), deep learning (DL) and natural language processing (NLP). They allow you to model complex processes, analyze large data sets and make predictions, which is extremely important in the pharmaceutical industry.

In the field of pharmaceutical design and development of new drugs, AI is used to identify potential drug targets, automate testing processes and optimize clinical and pharmacological models, personalized pharmacotherapy regimens, and train educational personnel for this area. Through the analysis of genomic and proteomic data, AI algorithms contribute to the personalization of therapy and the creation of innovative drugs [13].

Machine Learning, Deep Learning, and Natural Language in the Context of Pharmaceutical Design

Machine learning (ML) is a fundamental approach in AI that allows systems to learn from data without explicit programming. In the pharmaceutical industry, ML is used to predict molecular properties, model drug interactions, and analyze treatment efficacy.

Deep learning (DL), a subset of ML, uses artificial neural networks to analyze complex relationships in medical data. Its applications in pharmaceuticals include automatic image analysis, which helps in diagnosing diseases from medical images [14].

Natural language processing (NLP) is used to analyze text data, which is useful in studying medical records, analyzing side effect reports, and classifying scientific publications. NLP technologies allow for the automatic processing of large amounts of information and the discovery of new patterns in pharmaceutical research [12].

AI Algorithms and Tools in Medical Data Analysis

AI is actively used for medical data analysis due to a wide range of algorithms and technologies.

Key AI algorithms are shown in Fig. 1.

Finding new drug molecules using AI

Traditional methods of drug discovery are based on lengthy experimental studies. However, AI allows for significantly accelerating this process. Using deep learning algorithms and computational chemistry methods, it is possible to predict the interaction of molecules with biological targets even before laboratory experiments are conducted.

One of the most effective approaches is the use of generative models, such as deep neural networks (DNNs) and autoencoders, that generate new chemical structures with desired properties. For example, the DeepChem and AtomNet algorithms analyze huge databases of known drug compounds and predict new promising molecules [11].

In addition, AI-based structural analysis methods are used to predict the interaction of ligands with protein targets, which significantly increases the efficiency of screening potential new drugs [14].

Optimization of clinical trials and minimizing errors

Clinical trials are the most expensive and time-consuming stage of drug development. AI helps to optimize this process, reducing the number of experiments required and increasing the accuracy of results.

The main capabilities of AI in clinical trials are shown in Fig. 3.



Fig. 1. Key AI algorithms.

Popular AI tools in medicine and pharmaceuticals include four, as shown in Fig. 2.



Fig. 2. Popular AI tools in medicine and pharmacy.

AI-based systems such as IBM Watson analyze historical data on clinical trials and help plan new experiments, reducing their duration and costs [15].

Predicting clinical and pharmacological properties and toxicity of new drugs

The clinical-pharmacological properties and toxicological profile of a drug are important parameters for determining its safety and efficacy. AI allows predicting these properties even before laboratory studies are conducted, which significantly accelerates the process of pharmaceutical design and drug development.

Key methods for predicting the safety and efficacy of new drugs are shown in Fig. 4.

Studies have shown that the use of Random Forest and Support Vector Machines algorithms allows predicting the toxicity of new drugs with an accuracy of over 85% [15].

Thus, AI plays a key role in modern pharmaceuticals, pharmaceutical design. It allows significantly reducing the time for developing new drugs, optimizing clinical trials, and ensuring safety. effectiveness.

AI in personalized medicine and pharmaceuticals

Personalized medicine is a modern approach to pharmacotherapy, which is based on the individual characteristics of the patient, including his genetic profile, lifestyle, and other factors. AI opens new opportunities for personalizing pharmacotherapy. It allows predicting the effectiveness of drugs for specific patients and reducing the risks of side effects.



Fig. 3. Key AI capabilities in clinical trials.



Fig. 4. Key methods for predicting the safety and efficacy of new drugs.

Personalized treatment using genetic data analysis

Genetic tests allow determining how the patient's body will react to certain drugs. The introduction of AI into the analysis of genomic data allows for faster and more accurate identification of biomarkers responsible for the effectiveness and safety of drugs. The main areas of application of AI in personalized medicine and pharmaceuticals are shown in Fig. 5.



Fig. 5. Main directions of application of AI in personalized medicine and pharmaceuticals.

Thanks to deep learning algorithms, such as AlphaFold, rapid modeling of protein structures becomes possible, which helps in the development of individual drugs [16].

Increasing the effectiveness of treatment through individual approaches

AI allows you to create individual treatment strategies, pharmacotherapy, which consider the unique characteristics of each patient.

Main capabilities of AI in personalized medicine and pharmaceuticals are shown in Fig. 6.



Fig. 6. Main capabilities of AI in personalized medicine and pharmaceutics.

Such approaches are already used in the treatment and pharmacotherapy of rare diseases, when standard methods do not give the expected effect. For example, AI is used to select pharmacotherapy for cystic fibrosis and neurodegenerative diseases [16].

Thus, AI makes personalized medicine and pharmaceutics more accessible and effective, allowing to adapt treatment and pharmacotherapy to the individual needs of patients and reducing the risks of complications.

AI in the pharmaceutical design of new drugs

AI plays an important role in improving the development, production, and testing of new drugs. Its algorithms can optimize each stage of drug creation: from automating the synthesis of substances to monitoring the quality of finished products. Thanks to AI, pharmaceutical companies reduce the time for drug development, minimize errors and improve safety standards.

Automation of production and quality control

The introduction of AI into the production processes of the pharmaceutical industry allows to significantly increase the efficiency and accuracy of technological operations.

The main advantages of AI in the production of medicines are shown in Fig. 7.



Fig. 7. Key benefits of AI in drug manufacturing.

This approach not only improves the quality of drugs, but also ensures compliance with the requirements of regulatory authorities such as the FDA and EMA.

AI in optimizing testing and safety monitoring processes

Pharmaceutical testing is a long and complex process that includes preclinical studies, clinical trials, and post-marketing monitoring. The implementation of AI significantly accelerates the analysis of the safety and efficacy of drugs.

The main capabilities of AI in drug testing are shown in Fig. 8.



Fig. 8. Key AI capabilities in drug testing.

Companies are already using tools such as IBM Watson and BenevolentAI to analyze clinical trial data and predict the effectiveness of new drugs [15].

Thus, AI can significantly reduce testing time, reduce the risks of failed trials, and ensure safer entry of new drugs into the market.

Regulation and ethics of AI in medicine and pharmacy

The development of AI in the pharmaceutical industry opens significant opportunities for improving diagnostics, treatment, pharmacotherapy, and drug production. At the same time, the use of AI in medicine and pharmacy raises several ethical questions and requires clear regulatory approaches to ensure safety, effectiveness, and fairness.

Ethical issues of using AI in medicine and pharmacy

The main ethical challenges of implementing AI in the pharmaceutical sector are (Fig. 9).

The ethical principles of using AI in medicine and pharmacy should be based on ensuring fairness, safety, responsibility and explainability of algorithmic decisions.

The impact of AI on industry standards and regulation

Regulatory bodies are already beginning to actively respond to the growing role of AI in medicine and pharmacy.

The main areas of regulation are shown in Fig. 10.



Fig. 9. The main ethical challenges of implementing AI in medicine and pharmacy.



Fig. 10. Main areas of regulation.

In general, AI regulation in medicine and pharmacy should be dynamic, consider rapid technological changes, balancing innovation, and protection of public interests.

Future use of AI in medical and pharmaceutical research

AI has significant potential for revolutionary changes in the field of healthcare. Further development of deep learning (DL), machine learning (ML) and natural language processing (NLP) technologies opens new opportunities for reducing the time and cost of drug development [17].

One of the key areas of development is personalized medicine and pharmaceuticals, which is based on the analysis of genetic data and individual biological markers. The use of AI allows for the creation of personalized treatment regimens and optimization of drug dosages [18].

In addition, considerable attention is paid to the use of AI in the study of new antiviral agents, which allows for the analysis of immune repertoires and the creation of effective vaccines [19].

Technical and Regulatory Barriers to Widespread AI Adoption

Despite the great promise, the large-scale adoption of AI in medicine and pharmaceuticals faces several technical and regulatory hurdles.

- First, the quality and availability of large datasets are critical for effective training of AI models. However, significant limitations in standardization of medical data complicate their use in pharmaceutical research [12, 17].
- Second, the issue of ethics and data privacy remains one of the biggest challenges. The use of personalized patient information to train AI algorithms raises concerns about data security, especially in the context of GDPR and other regulatory requirements.

In addition, regulatory authorities do not yet have clear protocols for assessing the effectiveness and safety of AI-assisted pharmaceutical developments. The lack of harmonized standards and methodologies for validating AI models may slow down their implementation in the pharmaceutical sector [20].

However, despite the above difficulties, the gradual improvement of AI technologies and the development of new regulations will contribute to the further integration of artificial intelligence into the medical and pharmaceutical industry, opening new opportunities for the development of innovative personalized therapeutic approaches.

The role of AI in the future development of medicine, pharmacy, and education

AI plays an increasingly important role in the pharmaceutical industry, pharmaceutical design. AI offers new approaches to the search, development, and optimization of new drugs. Due to the ability to process large amounts of data and analyze complex biological interactions, AI significantly reduces the time and costs of developing new drugs [1, 9].

The development of machine learning algorithms contributes to increasing the efficiency and accuracy of predicting clinical and pharmacological, pharmacokinetic and pharmacodynamic parameters. It allows you to avoid potential toxic effects and select optimal dosages of drugs [2, 10].

In addition, AI plays a key role in the development of personalized medicine and pharmaceuticals. It allows you to adapt therapeutic strategies to the genetic characteristics of each patient [21]. The role of AI in education, training of medical and pharmaceutical personnel to master the latest learning technologies for use in personalized medicine, pharmaceutical design of new drugs is undeniable [17].

Prospects for patients, healthcare professionals and pharmaceutical professionals

The introduction of AI into healthcare and pharmaceutical practice has a significant positive impact on the quality of healthcare and pharmaceutical provision. For patients, this means access to more effective, safe, high-quality medicines, as well as the possibility of receiving individualized pharmacotherapy regimens based on their genetic and clinical data [14, 21].

Healthcare professionals are provided with powerful tools for diagnosing and predicting the development of diseases, which allows for more accurate and timely treatment. For example, AI

algorithms already help in the diagnosis of respiratory diseases such as asthma, COPD and pulmonary fibrosis by analyzing CT and X-ray images [13, 22].

However, the introduction of AI is also accompanied by certain challenges, in particular the need to regulate the ethical and regulatory aspects of its use. Particular attention is required to the issue of personal data protection, as patients must be confident in the security of their medical records [22].

In general, the use of artificial intelligence in pharmaceuticals and medicine opens up new prospects for increasing the effectiveness of treatment and improving the quality of life of patients. Further development of this technology will depend on the successful overcoming of regulatory and ethical barriers, as well as on the integration of AI into everyday medical and pharmaceutical practice, pharmaceutical design and education [23, 24].

Conclusions. AI is significantly transforming medicine, the pharmaceutical industry and training for these areas. It accelerates the processes of discovery, development, testing and personalization of medicines. The use of AI helps to optimize the search for new drugs, increase the efficiency of clinical trials, predict the clinical, pharmacological and pharmacokinetic properties of drugs. It allows to reduce costs and reduce the time to market for medicines. Personalized medicine and pharmaceuticals, based on the analysis of genetic data using AI, provide an individualized approach to treatment, pharmacotherapy, and reduce the risks of complications. At the same time, the further development of AI technology will depend on improving the regulatory framework, ensuring the ethics of using algorithms and their integration into medical and pharmaceutical practice. Despite the challenges, AI opens up new opportunities for creating innovative therapeutic approaches and improving the quality of life of patients. Training medical and pharmaceutical personnel using AI technologies contributes to the implementation of personalized medicine, innovative pharmaceutical design methods in the development of new drugs. Further research is ongoing.

Declaration of conflict interest. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors confirm that they are the authors of this work and have approved it for publication. The authors also certify that the obtained clinical data and research were conducted in compliance with the requirements of moral and ethical principles based on medical and pharmaceutical law, and in the absence of any commercial or financial relationships that could be interpreted as potential conflict of interest.

Funding. This research wasn't funded by any private or governmental body.

Data availability statement. The datasets analyzed during the current study are available from the corresponding author on reasonable request.

References.

1. Lavoshnik O., Gryzodoub O., Diachenko L. et al. (2025). State Pharmacopoeia of Ukraine and Pharmaceutical Law: State Quality Standard for Medicines for Standardization and Quality Control During Circulation in Healthcare and Pharmacy Sectors. *SSP Modern Pharmacy and Medicine*. 2025. Vol.5. No.1. P.1-20. URL: https://doi.org/10.53933/sspmpm.v5i1.176
2. Shapovalova V., Shapovalov V., Osyntseva A. et al. Organization of the Pharmaceutical Business, Industrial Pharmacy and Forensic Pharmacy Concerning the Competences of Quality Management During the Circulation of Medical Products: GxP Standards. Actual Problems of Medicine and Pharmacy. 2022. Vol. 3. No 2. P. 1-20. DOI: https://doi.org/10.52914/apmp.v3i2.44
3. Shapovalov V., Veits O. Medical and Pharmaceutical Law in Erasmus+: Study of the Disciplines by Medical Students as a Basis for Training of Healthcare Professionals in Prevention of Medical Errors and Crimes. SSP Modern Law and Practice. 2024. Vol. 4. 4. P. 1-17. DOI: https://doi.org/10.53933/sspmlp.v4i4.169
4. Shapovalova V. The ICD-11 For the Twenty-First Century: The First View from The Organizational, Legal, Clinical and Pharmacological Aspects. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No 1. P. 1-13. DOI: https://doi.org/10.53933/sspmpm.v2i1.37
5. Shapovalova V. The main changes in the ICD-11. Preprint. Version 1. 2024. DOI: https://doi.org/10.61829/7fvvxa57.

6. Shapovalov V.V., Gudzenko A.O., Shapovalova V.O. et al. Clinical and pharmacological, classification and legal, nomenclature and legal distribution of medicines for pharmacotherapy of depression among combatants (F32-33). Health of Society. 2021. Vol. 7 No. 4. P. 181-186. DOI: https://doi.org/10.22141/2306-2436.7.4.2018.148361
7. Shapovalov V. Multidisciplinary study of medical errors in the system of legal relations between "Doctor-Patient-Pharmacist-Advocate" during the circulation of drugs. SSP Modern Pharmacy and Medicine. 2023. Vol. 3. No. 2. P. 1-11. DOI: https://doi.org/10.53933/sspmpm.v3i2.88
8. Nevzghoda O., Shapovalov V., Osyntseva A. et al. Codeines medicine: ABC/VED analysis, effectiveness and rationality of application. Annals of Mechnikov Institute. 2024. No.4. P.29–34. URL: https://doi.org/10.5281/zenodo.14275098
9. Shapovalova V. Forensic and pharmaceutical risks in the organization of pharmacotherapy of covid, post-covid and long-covid disorders. COVID-19 and vaccination practice standards. SSP Modern Pharmacy and Medicine. 2022. Vol. 2. No. 4. P. 1–24. URL: https://doi.org/10.53933/sspmpm.v2i4.69
10. Gryzodoub O., Shapovalov V. Quality Systems in Pharmacy: Multidisciplinary Context of the State Pharmacopoeia of Ukraine. SSP Modern Law and Practice. 2023. Vol. 3. No. 1, P. 1-23. DOI: https://doi.org/10.53933/sspmlp.v3i1.81
11. Vora L.K., Gholap A.D., Jetha K. et al. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics*. 2023. Vol.10. Iss.15(7). P.1916. DOI: 10.3390/pharmaceutics15071916. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10385763/
12. Saha A., Singh I. Harnessing the Power of Artificial Intelligence in Pharmaceuticals: Current Trends and Future Prospects. *Intell. Pharm*. 2024. DOI: 10.1016/j.ipha.2024.12.001
13. Yadav P., Rastogi V., Yadav A. et al. Artificial intelligence: A promising tool in diagnosis of respiratory diseases. *Intell. Pharma*. 2024. DOI: 10.1016/j.ipha.2024.05.002. URL: https://doi.org/10.1016/j.ipha.2024.05.002
14. Taherdoost H., Ghofrani A. AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. *Intell. Pharma*. 2024 DOI: 10.1016/j.ipha.2024.08.005. URL: https://doi.org/10.1016/j.ipha.2024.08.005
15. Miah R. Artificial intelligence in anti-dengue drug development. *Intell. Pharma.* 2024. DOI: 10.1016/j.ipha.2024.01.006. URL: https://doi.org/10.1016/j.ipha.2024.01.006
16. Unleashing the potential of Artificial Intelligence in medicine: transforming diagnostics and treatment. Ukrainian Association of Development IT Medicine. 01.09.2023. URL: https://www.esemi.org/ai_med/
17. Nikitha B.S., Roopa K., Kynshi S.L. et al. Artificial intelligence and internet influence on drug utilization: Exploring self-medication trends in South Indian pharmacy students. *International Journal of Pharmacy*. 2024. DOI: 10.1016/j.ipha.2024.06.001
18. EFPIA. *EFPIA position on the use of artificial intelligence in the medicinal product lifecycle*. October 2024. URL: https://www.efpia.eu/media/tzeavw1t/efpia-position-on-the-use-of-artificial-intelligence-in-the-medicinal-product-lifecycle.pdf
19. European Medicines Agency. The use of Artificial Intelligence (AI) in the medicinal product lifecycle. URL: https://www.ema.europa.eu/en/use-artificial-intelligence-ai-medicinal-product-lifecycle.
20. European Medicines Agency. Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle. September 9, 2024. EMA/CHMP/CVMP/83833/2023. URL: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf.
21. Drug Development & Delivery. Artificial intelligence: Accelerating drug discovery and development – The AI revolution is here. URL: https://drug-dev.com/artificial-intelligence-accelerating-drug-discovery-development-the-ai-revolution-is-here/.
22. Roche. Artificial intelligence and machine learning: Revolutionising drug discovery and transforming patient care. URL: https://www.roche.com/stories/ai-revolutionising-drug-discovery-and-transforming-patient-care

23. The TED-Ed Student Talks program provides free, customizable events for educators to support their students in discovering, developing, and sharing their ideas with each other and the world. TedEd. URL: https://ed.ted.com/student_talks?utm_medium=website_sailthru&utm_source=talk_exitintent&utm_campaign=ted-ed-apps&utm_content=march15cycle
24. Can AI help develop new drugs? Ted. URL: https://www.ted.com/talks/aviv_regev_can_ai_help_develop_new_medicines